Venus Leg Ulcers
Conditions
Brief summary
The purpose of this trial is to determine if wounds with elevated protease activity (EPA) treated with targeted interventions such as protease modulating therapies can improve clinical and economic outcomes. Multi-centre VLU study to investigate efficacy of WOUNDCHEK™ on EPA wounds
Detailed description
The purpose of this trial is to determine if wounds with elevated protease activity (EPA) treated with targeted interventions such as protease modulating therapies can improve clinical and economic outcomes. It is hypothesized that protease modulating dressings may provide significantly better clinical outcomes on EPA wounds over current standard of care. Wounds with EPA will be determined using a new POC diagnostic test, WOUNDCHEK™ Protease Status, and the efficacy of PROMOGRAN®, a protease modulating therapy will be determined against standard of care (moist wound healing and compression) in VLU wounds in both elevated EPA and low protease activity wounds.
Interventions
DEVICEPromogran
Promogran is a collagen/ORC dressing which modulates the wound environment
DEVICECoban 2 layer
Compression bandage
Sponsors
Systagenix Wound Management
Study design
Allocation
RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* Men and women aged ≥ 18 years old * Patients with a leg ulcers of venous aetiology as determined by ankle brachial pressure index (ABPI) ≥ 0.8 and able and willing to use appropriate compression therapy * Duration of ulcer ≥ 6 weeks ≤ 3 years * Ulcer is ≥ 1 cm2 ≤ 100cm2 no length longer than 10cm * The patient must be able to understand the trial and provide written informed consent * No local or systemic signs of infection, with normal CRP and leukocyte levels below 10 000 * Wound has not been treated with PROMOGRAN® in 4 weeks prior to inclusion
Exclusion criteria
* Leg ulcers that do not have venous aetiology as determined by not been suitable for compression therapy and having an ABPI ≤ 0.8 * Leg ulcer smaller than 1cm2 and larger than 100cm2 and has any length longer than 10cm * Wound duration of less than 6 weeks or longer than 3 years * Known hypersensitivity to any of the wound dressing used in the trial * Current local or systemic antibiotics in the week prior to inclusion * Clinical infected wound as determined by the presence of 3 or more of the following clinical signs: perilesional erythema, pain between two dressing changes, malodorous wound, abundant exudate and oedema. * Progressive neoplastic lesion treated by radiotherapy or chemotherapy * Prolonged treatment with immunosuppressive agents or high dose corticosteroids * Patients who have a current illness or condition which may interfere with wound healing in the last 30 days (carcinoma, connective tissue disease, autoimmune disease or alcohol or drug abuse) * Life expectancy of \<6 months * Patients with uncontrolled diabetes as determined by Hb-A1c ≥ 12% ( = Hb-1CIFCC ≥ 107.65 mmol/mol) * Patients who have participated in a clinical trial on wound healing within the past month * Patients who are unable to understand the aims and objectives of the trial * Patients with a known history of non adherence with medical treatment * Females who are pregnant * Subject has Acquired Immunodeficiency Syndrome (AIDS) or is known to be infected with Human Immunodeficiency Virus (HIV) * Subject has viral hepatitis
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| The primary end-point of this study will be to identify EPA wounds using WOUNDCHEK™ Protease Status diagnostic test | 12 weeks | The primary end-point of this study will be to identify EPA wounds using WOUNDCHEK™ Protease Status diagnostic test, and to compare the healing outcomes of two treatment regimes (PROMOGRAN®, a protease modulating therapy and current standard of care) on chronic wounds with EPA. An improved healing outcome for venous leg ulcers will be defined as the proportion of wounds which reach a minimum 30% percentage reduction in wound surface area over a four-week treatment period. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| The average percentage change in protease activity levels pre and post treatment | 12 weeks | The proportion of wounds achieving wound closure (defined as a restoration of a complete epithelial cover) at twelve weeks and the average time to wound closure. The relative cost effectiveness of both treatment regimes when they are targeted appropriately; PROMOGRAN®, a protease modulating therapy targeted to wounds with EPA and standard of care to wounds with LPA.Healing outcomes for standard of care on EPA wounds as compared to LPA wounds. Healing outcomes for PROMOGRAN®, a protease modulating therapy on EPA wounds as compared to LPA wounds. |
Countries
Germany, Italy, United Kingdom, United States
Contacts
Primary ContactBreda Cullen, PHD
Outcome results
None listed